glp1

GLP-1(7-36), amide (MKC 253) 是一种生理性肠降血糖素，能够刺激胰岛素分泌。

GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr- -) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003). GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr- -) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2 References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003).

GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells.

GLP-1(9-36)amide 是胰高血糖素样肽-1 (7-36) amide 的主要代谢产物，对人胰腺 GLP-1受体具有拮抗作用。

[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH 是一种黄体激素释放激素 (LHRH) 类似物，可作为 GnRH 受体拮抗剂。

1H-Benzimidazole-6-carboxylic acid 是GLP-1 receptor 激动剂。

The GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide, a glucagon-like peptide 1 receptor (GLP-1) agonist.

GLP-1 receptor agonist 3 is a GLP-1 receptor agonist,Example 4A-1, has EC50s of 1.1 nM and 13 nM in Clone H6 and Clone C6 cell lines assay, respectively.

GLP-1(28-36)amide acetate 抑制线粒体通透性转变，具有抗氧化、抗糖尿病和心脏保护活性。

GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutral endopeptidase (NEP), is a significant product. It functions as an antioxidant and primarily targets the mitochondrion, where it effectively inhibits mitochondrial permeability transition (MPT). This compound exhibits anti-diabetic properties and demonstrates cardioprotection effects[1].

GLP-1(7-37) acetate 是肠道胰岛素激素，能够促进葡萄糖诱导的胰岛素分泌。

GLP-1(7-36), amide TFA is a prominent intestinal hormone known to stimulate glucose-induced insulin secretion from β cells[1].

GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of 64.5 nM, and is utilized in diabetes treatment research.

GLP-1(32-36)amide is a pentapeptide compound derived from the C terminus of the glucoregulatory hormone GLP-1. This compound has shown potential in inhibiting weight gain and regulating glucose metabolism in diabetic mice[1][2].

Anti-GLP1R Antibody 是一种靶向GLP1R并在CHO细胞中表达的人源抗体。其同型对照请参阅Human IgG1 kappa, Isotype Control。

Semaglutide Acetate 是胰高血糖素样肽 1 (GLP-1) 受体的激动剂，可用于治疗 2 型糖尿病的研究。

Avexitide (Exendin-3 (9-39) amide) 是一种特异竞争性的glucagon-like peptide-1 (GLP-1)受体拮抗剂。

Liraglutide (Liraglutida) 是一种人工合成的胰高血糖素样肽-1 (GLP-1) 的类似物，是 GLP-1 受体的激动剂。Liraglutide 可以用于治疗 2 型糖尿病和慢性肥胖症。

Tirzepatide (LY-3298176) 是葡萄糖依赖性多肽 (GIP) 和胰高血糖素样肽-1 (GLP-1) 受体双重激动剂，具有神经保护活性，可改善血压并降低低密度脂蛋白 （LDL） 胆固醇和甘油三酯，可以用于研究糖尿病和肥胖症。

Semaglutide 是人胰高血糖素样肽-1受体激动剂，是一种人胰高血糖素样肽-1 的长效类似物。它有用于 2 型糖尿病研究的潜力。

Retatrutide (LY3437943) 是胰高血糖素受体、葡萄糖依赖性促胰岛素多肽受体和胰高血糖素样肽-1 受体三重激动剂,对GCGR、GIPR 和 GLP-1R 具有抑制作用。Retatrutide 可用研究肥胖症。

Des His1, Glu8 Exendin-4 是一种胰高血糖素样肽-1 受体 (GLP-1-R) 拮抗剂，可调节血糖。Des His1, Glu8 Exendin-4 用于研究糖尿病和肥胖。

GLP-1R modulator C5 是一种小分子 GLP-1R 正变构调节剂，通过跨膜位点增强GLP-1与GLP-1R的结合，可用于研究 II 型糖尿病。。

Lotiglipron (PF-07081532) 是一种具有口服活性和有效性的 GLP-1R 激动剂，能够降低血糖和体重，可用于研究 2 型糖尿病 (T2DM) 和过度肥胖。